Is Alcohol Good, Bad, or Neutral for Cardiovascular Health?

In the 2018 Guidelines on Hypertension, commandment no. 6 states that we should make lifestyle interventions such as sodium restriction, healthy eating, regular exercise, weight control, and smoking cessation, and also alcohol moderation.

¿El alcohol es bueno, malo o neutro para la salud cardiovascular?It is clear that heavy alcohol consumption induces hypertension and may probably be one of the main causes of secondary hypertension, but few sources detail what a moderate or “healthy” consumption is.

There are consistent observational data to indicate that there is an association between alcohol use and cardiovascular events, and that, as a whole, it is U-shaped. In other words, low or moderate alcohol consumption (up to one drink or 12.5 g alcohol per day in women and up to two drinks or 25 g per day in men) are associated with a reduced risk of overall cardiovascular events and mortality, compared with absolute abstinence or excessive consumption.


Read also: Progress of patients with hypertrophic cardiomyopathy treated with alcohol septal ablation.


The alcohol content of a beverage is expressed in degrees and it measures the content of absolute alcohol in 100 cm3, i.e. the alcohol percentage in a beverage. For example, if we have a 13-degree wine, that means that it contains 13 cm3 of absolute alcohol for every 100 cm3 of wine. In product labels, alcoholic content is expressed as (°) or vol%. The calculation would be as follows: consumed volume (in cm3) × alcohol content × 0.8, and then divide all by 100. We must ask the patient about the type of beverage (so as to get the alcohol content) and the amount consumed (so as to get the volume, in cm3) in order to calculate whether such consumption is good or bad for their health.

In any case, this generalization masks important aspects that merit closer examination.

Patterns of drinking, the type of alcohol consumed, and factors associated with alcohol consumption, such as socio-economic status and dietary patterns, may modify significantly such generalization. Well-established cardiac disease also implies differences, particularly for patients with left ventricular dysfunction.


Read also: Alcohol dilemma: Cardiovascular enjoyment and benefits versus cancer.


Furthermore, the effects of alcohol on coronary pathologies may differ from its effects on arrhythmias or heart failure risk, and they may also differ on ischaemic stroke and intracerebral haemorrhage.

It is important to consider that even if there is a modest cardiovascular benefit derived from moderate consumption, it may imply a risk of cancer and cirrhosis.

Finally, the data supporting this modest benefit have emerged from observational studies that are subject to many methodological limitations and potential confounding variables.


Read also: MitraClip in the “Real World”.


Consequently, for the time being, it may be better to advise restraint as opposed to support consumption to reduce cardiovascular risk.

Original title: Are the Cardiac Effects of Alcohol Good, Bad, or Neither?

Reference: Leong DP et al. Eur Heart J. 2019 Mar 1;40(9):712-714.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

SPYRAL Program: 3-Year Outcomes in Patients Treated with Renal Denervation

Hypertension is the leading modifiable risk factor for cardiovascular disease and remains a major global health challenge, affecting more than one billion adults worldwide.  Despite...

Coronary Obstruction During TAVI: A New Volumetric Index to Consider

Coronary obstruction during TAVI is an uncommon but potentially catastrophic complication, particularly in valve-in-valve procedures, in anatomies with small sinuses of Valsalva, low coronary...

EARLY TAVR: Impact of Age on Outcomes of Early TAVR in Asymptomatic Patients

Asymptomatic severe aortic stenosis represents an increasingly common clinical challenge. Although current guidelines recommend intervention once symptoms develop or left ventricular dysfunction occurs, concerns...